Advertisement
U.S. markets open in 9 minutes
  • S&P Futures

    5,308.50
    +0.25 (+0.00%)
     
  • Dow Futures

    40,180.00
    +36.00 (+0.09%)
     
  • Nasdaq Futures

    18,501.00
    -2.75 (-0.01%)
     
  • Russell 2000 Futures

    2,141.20
    +2.80 (+0.13%)
     
  • Crude Oil

    82.45
    +1.10 (+1.35%)
     
  • Gold

    2,232.70
    +20.00 (+0.90%)
     
  • Silver

    24.77
    +0.02 (+0.07%)
     
  • EUR/USD

    1.0812
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2636
    -0.0002 (-0.02%)
     
  • USD/JPY

    151.3270
    +0.0810 (+0.05%)
     
  • Bitcoin USD

    70,603.77
    -571.58 (-0.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,955.03
    +23.05 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Mark Cuban Aims To Disrupt A $365 Billion Industry – With The Only Startup That Bears His Name

Billionaire venture capitalist Mark Cuban has founded or invested early in hundreds of startup companies over the years. But only one of them, founded in January 2022, bears his name.

The Mark Cuban Cost Plus Drug Co. seeks to disrupt the $365 billion U.S. prescription drug market, which is rife with pricing inefficiencies. For example, one tablet of the Type 2 diabetes treatment Metformin costs over $500 at retail prices. But through Cuban’s company, the same tablet is just $46.20.

The company offers 350 prescription drugs at cost, plus a fixed 15% margin that still makes some prescription drugs significantly cheaper than their retail prices. The savings are made possible in part by eliminating the middleman in the prescription drug industry: Cuban’s company bypasses health insurers to negotiate directly with drug manufacturers.

To stay updated with top startup investments, sign up for Benzinga’s Startup Investing & Equity Crowdfunding Newsletter

The startup could have saved Medicare up to $3.6 billion in 2020 alone, according to a study by Harvard Medical School. But as significant as that number is, it pales in comparison to an even lower-hanging fruit in the fight to drive down healthcare costs: targeting the nationwide stress epidemic.

Stress costs the U.S. economy as much as $300 billion per year, according to the American Psychological Association. A huge source of this is healthcare costs, with 65% of households reporting high levels of stress or anguish over treatment costs. Cuban’s company, should it succeed in slashing prescription drug prices across the board, could provide tremendous relief on this front.

The healthcare market has been increasingly filled with innovative startups looking to disrupt the broken industry. For example, founded in 2017, Aura Health is the startup behind the all-in-one mental wellness app offering the world’s most extensive content, community, and coaching offered by coaches & therapists worldwide

Already used by 7 million people, Aura is the world’s leading marketplace for mental wellness.

See more on startups investing from Benzinga.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Mark Cuban Aims To Disrupt A $365 Billion Industry – With The Only Startup That Bears His Name originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement